Liquidia Corporation

Liquidia Corporation is a pulmonary-drug specialty pharma — YUTREPIA (dry-powder inhaler for pulmonary arterial hypertension) is the commercial asset, and the setup is entirely about a pending patent-litigation ruling versus United Therapeutics.

• The commercial ramp is genuinely huge: Q2 revenue crossed $171.7M (up 42x YoY off a launch base), 95%+ gross margins, Q1 revenue grew 42x YoY to $132.9M, and the sell side models FY26 revenue at ~$725M rising to ~$1.18B in 2027 — the launch has exceeded even bullish models, and a new 70K-sqft manufacturing facility is nearly ready.
• The binary catalyst is imminent: Judge Andrews is expected to rule on the UTHR (United Therapeutics) patent-infringement lawsuit; the bulls target $90-150 on a Liquidia win and $80 on a 5% royalty compromise — a specific dated legal outcome that decides the equity value range.
• The insider signal is the loudest bear tell: CFO Jason Adair sold ~$5.09M on August 21 after M-Exempt exercises, and director Rielly-Gauvin sold combined ~$4.08M across August 19-20 — a real insider cluster into strength ahead of a binary event; put buying is also elevated.

Everything happens on Judge Andrews' ruling — a Liquidia win with clear patent-injunction language takes the stock past $90 fast; a UTHR win with a mandatory-royalty framework caps the stock near $50; a middle-ground 5% royalty compromise supports ~$80. The November 2 Q3 print is a secondary referee for continued YUTREPIA launch traction; watch also for any post-ruling settlement commentary.